94 related articles for article (PubMed ID: 12505454)
1. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit.
Ilbäck NG; Gunnarsson K; Persson R; Lindh U; Stålhandske T
Toxicology; 2003 Mar; 185(1-2):161-74. PubMed ID: 12505454
[TBL] [Abstract][Full Text] [Related]
2. A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits.
Ilbäck NG; Persson R; Gunnarsson K; Stålhandske T
J Pharmacol Toxicol Methods; 2002; 48(1):31-9. PubMed ID: 12750039
[TBL] [Abstract][Full Text] [Related]
3. Effects of EDTA on trace elements and cardiovascular function in the anesthetised rabbit.
Ilbäck NG; Stålhandske T; Lindh U
Biol Trace Elem Res; 2000 Aug; 76(2):133-48. PubMed ID: 11049228
[TBL] [Abstract][Full Text] [Related]
4. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model.
Reddy PN; Paul S; Sripathy MH; Batra HV
Toxicon; 2015 Sep; 103():106-13. PubMed ID: 26091873
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.
Nielsen SE; Zeuthen J; Lund B; Persson B; Alenfall J; Hansen HH
J Immunother; 2000 Jan; 23(1):146-53. PubMed ID: 10687147
[TBL] [Abstract][Full Text] [Related]
8. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
Alpaugh RK; Schultz J; McAleer C; Giantonio BJ; Persson R; Burnite M; Nielsen SE; Vitek L; Persson B; Weiner LM
Clin Cancer Res; 1998 Aug; 4(8):1903-14. PubMed ID: 9717818
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
10. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
12. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
Lando PA; Dohlsten M; Ohlsson L; Kalland T
Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
[TBL] [Abstract][Full Text] [Related]
13. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig.
Saha B; Jaklic B; Harlan DM; Gray GS; June CH; Abe R
J Immunol; 1996 Nov; 157(9):3869-75. PubMed ID: 8892617
[TBL] [Abstract][Full Text] [Related]
14. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
15. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
16. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
[TBL] [Abstract][Full Text] [Related]
17. The Cardiovascular Effect of Single Injection and Toxicologic Effects of Repetitive 2-Week Intravenous Administration of Activin A/BMP-2 Chimera in Beagle Dog.
Lee JH; Choe S; Han S
Cardiovasc Toxicol; 2018 Feb; 18(1):76-83. PubMed ID: 28612305
[TBL] [Abstract][Full Text] [Related]
18. Subchronic intravenous toxicity studies with gamma-cyclodextrin in rats.
Donaubauer HH; Fuchs H; Langer KH; Bär A
Regul Toxicol Pharmacol; 1998 Apr; 27(2):189-98. PubMed ID: 9671574
[TBL] [Abstract][Full Text] [Related]
19. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B.
Nagaki M; Muto Y; Ohnishi H; Yasuda S; Sano K; Naito T; Maeda T; Yamada T; Moriwaki H
Gastroenterology; 1994 Feb; 106(2):450-8. PubMed ID: 8299910
[TBL] [Abstract][Full Text] [Related]
20. Altered levels of trace elements in acute lung injury after severe trauma.
Wang G; Lai X; Yu X; Wang D; Xu X
Biol Trace Elem Res; 2012 Jun; 147(1-3):28-35. PubMed ID: 22139749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
